Stock 002728 TEYI PHARMACEUTICAL GROUP CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Teyi Pharmaceutical Group Co.,Ltd

Equities

002728

CNE100001WK6

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-07-08 pm EDT 		5-day change 1st Jan Change
7.34 CNY -8.48% Intraday chart for Teyi Pharmaceutical Group Co.,Ltd -11.14% -42.66%
Jul. 02 Tranche Update on Teyi Pharmaceutical Group Co.,Ltd's Equity Buyback Plan announced on June 12, 2024. CI
Jun. 12 Teyi Pharmaceutical to Buy Back Up to 120 Million Yuan Shares; Shares Up 3% MT

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • This company will be of major interest to investors in search of a high dividend stock.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
TEYI PHARMACEUTICAL GROUP CO.,LTD Stock Teyi Pharmaceutical Group Co.,Ltd
-42.66% 563M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+59.97% 827B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+38.38% 634B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.18% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.61% 319B
B-
ABBVIE INC. Stock AbbVie Inc.
+8.44% 294B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.68% 240B
B+
NOVARTIS AG Stock Novartis AG
+14.40% 221B
B-
ROCHE HOLDING AG Stock Roche Holding AG
+0.04% 219B
A+
AMGEN INC. Stock Amgen Inc.
+9.68% 167B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002728 Stock
  4. Ratings Teyi Pharmaceutical Group Co.,Ltd